1. CARDIAC RISK FACTORS  
- No h/o of DM, HTN, HLD

2. CARDIAC HISTORY  
- Reduced EF 60-->45% from ___ to several days ago
 
3. OTHER PAST MEDICAL HISTORY 
- Metastatic melanoma:  
PET CT ___ w/o residual FDG avid disease.   
On ___, patient initiated on ___ ___, "Randomized
Phase II/III Study of Nivolumab plus Ipilimumab plus 
Sargramostim
versus Nivolumab plus Ipilimumab in Patients with Unresectable
Stage III or IV Melanoma." ___ Ms. ___ was taken off
the study for reported worsening arthralgia and fatigue.  She 
was
extremely symptomatic bilateral hip pain and significant 
fatigue.

She received 2 doses of combination therapy ipi/nivo and
developed a grade 3 rash for which treatment was held.  With
high-dose steroids the rash quickly resolved and she resumed
maintenance nivolumab alone on ___. CT scans ___
showed complete resolution of malignant lymphadenopathy 
- Pulmonary HTN- follows with pulm OP and most recent PFTs
normal. PA pressure on echo mildly increased.
- Polycystic kidneys per pt report.
- Arthritis of low back, hips